Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART)

Roma Maguire,1 Lisa McCann,1 Grigoris Kotronoulas,2 Nora Kearney,3 Emma Ream,4 Jo Armes,4 Elisabeth Patiraki,5 Eileen Furlong,6 Patricia Fox,6 Alexander Gaiger,7 Paul McCrone,8 Geir Berg,9 Christine Miaskowski,10 Antonella Cardone,11 Dawn Orr,12 Adrian Flowerday,13 Stylianos Katsaragakis,5 Andrew Darley,14 Simone Lubowitzki,7 Jenny Harris,6 Simon Skene,15 Morven Miller,1 Margaret Moore,1 Liane Lewis,16 Nicosha DeSouza,17 Peter T Donnan17

ABSTRACT

OBJECTIVE
To evaluate effects of remote monitoring of adjuvant chemotherapy related side effects via the Advanced Symptom Management System (ASyMS) on symptom burden, quality of life, supportive care needs, anxiety, self-efficacy, and work limitations.

DESIGN
Multicentre, repeated measures, parallel group, evaluator masked, stratified randomised controlled trial.

SETTING
Twelve cancer centres in Austria, Greece, Norway, Republic of Ireland, and UK.

PARTICIPANTS
829 patients with non-metastatic breast cancer, colorectal cancer, Hodgkin’s disease, or non-Hodgkin’s lymphoma receiving first line adjuvant chemotherapy or chemotherapy for the first time in five years.

INTERVENTION
Patients were randomised to ASyMS (intervention; n=415) or standard care (control; n=414) over six cycles of chemotherapy.

MAIN OUTCOME MEASURES
The primary outcome was symptom burden (Memorial Symptom Assessment Scale; MSAS). Secondary outcomes were health related quality of life (Functional Assessment of Cancer Therapy—General; FACT-G), Supportive Care Needs Survey Short-Form (SCNS-SF34), State-Trait Anxiety Inventory—Revised (STAI-R), Communication and Attitudinal Self-Efficacy scale for cancer (CASE-Cancer), and work limitations questionnaire (WLQ).

RESULTS
For the intervention group, symptom burden remained at pre-chemotherapy treatment levels, whereas controls reported an increase from cycle 1 onwards (least squares absolute mean difference −0.15, 95% confidence interval −0.19 to −0.12; P=0.001; Cohen’s D effect size=0.5). Analysis of MSAS sub-domains indicated significant reductions in favour of ASyMS for global distress index (−0.21, −0.27 to −0.16; P=0.001), psychological symptoms (−0.16, −0.23 to −0.10; P=0.001), and physical symptoms (−0.21, −0.26 to −0.17; P=0.001). FACT-G scores were higher in the intervention group across all cycles (mean difference 4.06, 95% confidence interval 2.65 to 5.46; P<0.001), whereas mean scores for STAI-R trait (−1.15, −1.90 to −0.41; P=0.003) and STAI-R state anxiety (−1.13, −2.06 to −0.20; P=0.02) were lower. CASE-Cancer scores were higher in the intervention group (mean difference 0.81, 0.19 to 1.43; P=0.01), and most SCNS-SF34 domains were lower, including sexuality needs (−1.56, −3.11 to −0.01; P=0.03), physical and daily living needs (−2.8, −5.0 to −0.6; P=0.01). Other SCNS-SF34 domains and WLQ were not significantly different. Safety of ASyMS was satisfactory. Neutropenic events were higher in the intervention group.

CONCLUSIONS
Significant reduction in symptom burden supports the use of ASyMS for remote symptom monitoring in cancer care. A “medium” Cohen’s effect size of 0.5 showed a sizable, positive clinical effect of ASyMS on patients’ symptom experiences. Remote monitoring systems will be vital for future services, particularly with blended models of care delivery arising from the covid-19 pandemic.

TRIAL REGISTRATION
Clinicaltrials.gov NCT02356081.

Introduction
Despite guidance for patients and professionals on managing chemotherapy, associated symptoms...
are often poorly controlled.1 2 Undertreatment of symptoms results in poorer adherence to treatment, impaired health related quality of life, increased health service use, and mortality.3 5 Current symptom assessment mechanisms rely on patients recognising that symptoms are severe enough to warrant reporting. Uncertainty, delayed reporting, and inability to access 24 hour services frequently lead to toxicities not being recognised sufficiently quickly, placing patients’ safety at risk.6 7 Solutions are needed to expedite this process to improve patients’ outcomes and reduce costs.

Emergence of connected health has driven proliferation of remote monitoring solutions to support patients in community settings.8 9 These seem to be beneficial for people receiving chemotherapy, as they can circumnavigate the need for retrospective assessment, a process believed to “provide a weaker insight into actual symptom burden” as a result of recall bias.5 Such systems also enable patients’ data to be relayed to clinicians within minutes, enabling proactive symptom management. Previous research on remote monitoring systems in the chemotherapy context highlights their benefits for health related quality of life, symptom alleviation, avoiding unscheduled hospital admissions, survival, and cost effectiveness.10-14 However, this evidence is largely derived from trials, of short duration and from a single site/country, in people with advanced disease and without health economic evaluation.15 16 Evidence to inform scale-up across multiple countries and enable benefits to be realised globally is also limited.17

eSMART aimed to provide definitive high quality evidence on large scale benefits of remote monitoring in the management of toxicities of adjuvant and first line chemotherapy. eSMART was underpinned by earlier work, reflecting the Medical Research Council’s framework for designing and evaluating complex interventions.18 19 This showed the feasibility and acceptability of the Advanced Symptom Management System (ASyMS).20-23 The trial hypothesis was that, compared with standard care, ASyMS would lead to reductions in symptom burden, supportive care needs, anxiety, and work limitations and improvements in health related quality of life and self-care/self-efficacy during chemotherapy treatment in patients with breast cancer, colorectal cancer, Hodgkin’s disease, or non-Hodgkin’s lymphoma.

Methods

We conducted a multicentre, parallel group randomised controlled trial, using 1:1 allocation of study participants, between 31 March 2016 and 31 March 2019 (recruitment closed 14 December 2018). No significant changes were made to the methods during the trial,24 which was registered on Clinicaltrials.gov (NCT02356081). A data monitoring committee monitored progress and patient safety and met on average six monthly. The study is reported in accordance with the CONSORT statement for randomised controlled trials.

Setting and participants

Clinical or research staff from 12 cancer centres across Austria, Greece, Ireland, Norway, and the UK recruited participants. Participants attended for an enrolment visit before their first chemotherapy cycle, and written informed consent was obtained at this visit.

Eligible patients were aged ≥18 years; diagnosed as having breast cancer, colorectal cancer, Hodgkin’s disease, or non-Hodgkin’s lymphoma; scheduled to receive at least three cycles of two, three, or four weekly first line adjuvant chemotherapy or chemotherapy for the first time in five years; physically and psychologically fit to participate; and able to understand and communicate in the language of the country where recruited. The inclusion criteria were intentionally narrow to ensure that only patients treated with curative intent were recruited.

Participants were ineligible if they had distant metastasis (breast or colorectal cancer) or B symptoms (Hodgkin’s disease/non-Hodgkin’s lymphoma), were receiving concurrent radiotherapy or weekly chemotherapy (as timeframes covered by outcome measures were incompatible with weekly administration), had been diagnosed as having cancer or received chemotherapy within the previous five years, or were unable to provide informed consent.

Patients were initially recruited for the full duration of their chemotherapy. However, after five months, this was amended to participation for a maximum of six cycles to support recruitment and study timelines. This change was supported by previous ASyMS pilot work (unpublished) and literature showing that chemotherapy related symptoms are greatest during initial cycles of treatment.25 Consequently, participants used ASyMS when they were likely to gain most benefit.

Intervention

ASyMS (fig 1) provides real time, 24 hour monitoring and management of chemotherapy toxicity. Patients use ASyMS to complete a validated self-reported questionnaire (Daily Chemotherapy Toxicity Self-Assessment Questionnaire (DCTAQ)) that assesses 10 symptoms (nausea, vomiting, diarrhoea, constipation, mucositis, paraesthesia, sore hands/feet, flu-like symptoms/infection, tiredness, pain) and up to six additional symptoms.26 Patients are also asked to take and enter their body temperature by using a digital thermometer. Patients can access tailored, evidence based self-care advice (adapted from Macmillan Cancer Support resources) on ASyMS at any time.

ASyMS was translated into native languages (patient/clinician handsets, website, manuals). Patients completed the DCTAQ daily and whenever they felt unwell. “Real time” information was sent via a secure connection to the ASyMS server hosted by Docobo (https://www.docobo.co.uk/). After a review of local, national, and European best practice symptom management guidelines, and based on previous ASyMS studies, an evidence based clinical decision system, incorporating a symptom alerting algorithm and symptom specific management protocols, was
developed for ASyMS and verified by cancer experts from each clinical site before use.27

Symptom data were automatically evaluated in ASyMS and, when necessary, generated two types of alerts to hospital clinicians: amber, for persistent mild-moderate symptoms for which early intervention could prevent progression; and red, for chemotherapy emergencies such as neutropenic sepsis. Required response times were eight hours for amber alerts and 30 minutes for red alerts. When an alert was generated before an earlier alert had been dealt with (for example, if the patient completed a subsequent DCTAQ because symptoms had worsened), the alerts were linked.

Clinicians received alerts on dedicated handsets. For red alerts, clinicians were required to review patients’ symptom reports on ASyMS web pages and contact the patient for further review. For amber alerts, although viewing of reports was required, clinicians had the option of contacting patients. This discretionary element was incorporated following piloting in which clinicians indicated that in instances when a patient had generated an amber alert and had received self-care advice the previous day, contacting the patient the next day was often not necessary if the same alert was triggered again. During calls with patients, clinicians worked through evidence based clinical decision support systems embedded within ASyMS (fig 2) to inform symptom management interventions. On closing the alert, clinicians detailed actions taken—for example, self-care or acute oncology referral—and could select more than one action.

Participants in the intervention group used ASyMS for up to six cycles. They were trained by researchers/clinicians at each site on its use before starting chemotherapy. Participants in the control group received care as usual at their cancer centre and were advised to contact their clinician(s) through standard mechanisms (usually telephone triage) if they developed symptoms. This group received clinical input in line with each local site’s standard advice (verbal and written) on chemotherapy related symptoms and self-care.

Outcome measures
All participants completed patient reported outcome measures recording primary and secondary outcomes at baseline (enrolment, before randomisation, before chemotherapy) and before subsequent cycles. Patient reported outcome measures were collected in the cancer centre, via a tablet or secure weblink, coinciding with chemotherapy visits.

We collected data on adverse events and hospital admissions by reviewing case notes. Specifically, we defined a “neutropenic sepsis event” as development of fever (oral temperature >38.5°C or two consecutive readings of >38.0°C for two hours) and other signs of generalised, whole body infection in a patient with neutropenia (an absolute neutrophil count <0.5×10⁹/L, or <1.0×10⁹/L and “falling”). We also investigated hypothermia in the presence of neutropenia as a sign of neutropenic sepsis.28 Device related incidents were monitored during the trial according to European
The primary outcome measure was the Memorial Symptom Assessment Scale (MSAS), which measures 32 physical and psychological cancer related symptoms. Respondents reported on the occurrence, frequency, and severity of, and the distress associated with, each symptom over the preceding week. We calculated total MSAS score, representing symptom burden, by averaging items (that is, a potential range of 0-4). If >13% of items were missing, we treated the score as missing. Additionally, we calculated three subscale scores (global distress index, physical score, and psychological score) and treated them as secondary outcomes. The reliability and validity of MSAS are well established; in this study Cronbach’s $\alpha$ for total MSAS and MSAS physical, MSAS psychological, and MSAS global distress index subscales was 0.87, 0.82, 0.77, and 0.83, respectively.

Full details of the secondary outcomes measures are published in the eSMART study protocol. Briefly they included Functional Assessment of Cancer Therapy—General (FACT-G), assessing health related quality of life and four domains of wellbeing (physical, social/ family, emotional, and functional); Supportive Care Needs Survey Short-Form (SCNS-SF34), measuring supportive care needs in five domains (health system and information, psychological needs, physical and daily living, patient care and support, and sexual related); State-Trait Anxiety Inventory—Revised (STAI-R), measuring two types of anxiety (state (about an event) and trait (anxiety as a personal characteristic)); Communication and Attitudinal Self-Efficacy scale for cancer (CASE-Cancer), assessing cancer patients’ confidence and ability to engage in their care plus three dimensions (maintaining a positive attitude, understanding and participating in care, and seeking and obtaining information); and Work Limitations Questionnaire (WLQ), a 25 item scale corresponding to four domains (time management, physical demands, mental/interpersonal demands, and output demands), which was completed only by participants who were working.

Additional secondary outcomes assessed the effectiveness of ASyMS one year after the randomised controlled trial, evaluated the cost effectiveness of ASyMS, and assessed changes in clinical practice.
These secondary outcomes will be reported in forthcoming publications.

Adherence of patients and clinicians to intervention
We measured patients’ adherence by calculating compliance with DCTAQ for each patient, defined as the number of days on which at least one DCTAQ was completed divided by the number of days when a DCTAQ was available for completion. Participants were instructed to complete the DCTAQ daily but could complete additional DCTAQs any time they felt unwell. We calculated adherence rates by using the number of days on which DCTAQs were completed, rather than the number of DCTAQs completed, as participants may have completed more than one per day, over-inflating adherence rates. We calculated clinical adherence by measuring time taken for clinicians to first view ASyMS alerts on the server and calculating the percentage of linked amber and red alerts managed within the specified timeframes.

Randomisation and blinding
Surrey Clinical Trials Unit randomised patients remotely and independently using the Promasys system after patient consent and completion of baseline patient reported outcome measures and before the first chemotherapy cycle. Randomisation was stratified by site and cancer type. Research staff accessed the Promasys system remotely and completed a web based electronic case report form for the participant, and the allocation was assigned automatically. Random allocations were programmed by statisticians at the clinical trials unit using proc plan in SAS and run by staff independent of the trial team to ensure concealment of allocation. The nature of the intervention meant that blinding of patients was not possible, but patients were blinded to study hypotheses. Blinding of evaluators was achieved, as participants’ allocation was concealed from the statistical analysis team.

Sample size
During the planning of the trial, only limited literature was available, and it focused on the short version of MSAS (MSAS-SF) and on single patient groups followed over time. Chang et al reported clinically significant differences of 0.20–0.66 for a change in total MSAS-SF scores from baseline to one week later in patients with the worst cancer pain,36 and Dapueto et al reported absolute difference in global distress index of 0.38 and a Cohen’s effect size of 0.6 for a change in MSAS-SF global distress index scores between the first cycle and third month of adjuvant chemotherapy.37 Given the lack of data on MSAS from intervention studies, a priori we considered a small to moderate Cohen’s effect size of 0.25 to be a clinically significant difference in total MSAS scores. We then based sample size estimation based on differences in total MSAS scores between intervention and control groups of 1.45–1.30=0.15 from a previous randomised controlled trial.38 For a difference in total MSAS scores of 0.15 (SD 0.6), with baseline and four repeated measures after enrolment, we needed a sample of 776 participants (110 participants with Hodgkin’s disease or non-Hodgkin’s lymphoma, 333 participants with breast cancer, and 333 patients with colorectal cancer) to provide 90% power for a two sided hypothesis test at the 5% significance level. Allowing for 30% attrition, we increased the total study sample size to 1108. By February 2017 the attrition rate was lower than anticipated (10%); consequently, we reduced the sample size to 862.

Data analysis
We did an intention to treat analysis. We present study outcomes as means and standard deviations or percentages and denominators. Transformations were needed when distributions were non-normal, and we present medians and ranges. We present enrolment characteristics for the evaluable intention to treat sample. The primary outcome of total MSAS score is continuous, and we assessed it in a repeated measures analysis using linear and non-linear mixed models. We used a mixed model repeated measures analysis that uses all available data, assuming data are missing at random, throughout the analyses. Many participants rated their symptoms as not present (that is, 0), so the mixed model was implemented with a zero inflated γ distribution and identity link to provide results on the original scale.

Analyses tested the between group difference in means for the primary outcome—total symptom burden (total MSAS)—during chemotherapy for up to six cycles. We tested the primary hypothesis (reduced symptom burden in the intervention group over six cycles) through the regression parameter for the intervention versus control group, adjusting for baseline MSAS. We also adjusted for pre-specified variables: cancer type (breast cancer, colorectal cancer, Hodgkin’s disease, non-Hodgkin’s lymphoma), age (years), sex (male, female), number of comorbidities (0, 1-4, ≥5), and country (Austria, Greece, Republic of Ireland, Norway, and UK). We did pre-specified subgroup analyses by fitting trial arm by subgroup interaction parameters. If this test was significant at the 5% level, we estimated results separately for different subgroups. We used SAS software (version 9.4) and R 3.5 for all statistical analyses. We took a two sided P value of <0.05 as significant for all analyses unless otherwise specified.

Patient and public involvement
The European Cancer Patient Coalition was a partner in eSMART and advised throughout the study. It was involved in setting research priorities, defining research questions and outcome measures, and providing input into recruitment and data collection and dissemination.

Results
Recruitment
We recruited 840 patients; seven participants in the intervention group and four in the control group were ineligible after randomisation or immediately withdrew consent, leaving 415 and 414 analysable
Fig 3 | CONSORT diagram for eSMART. *Some people reported more than one reason for not wanting to take part, so total number of reasons exceeds number declined/excluded.
scores from Austria and Greece were significantly be similar to those from Norway and Ireland, whereas lymphoma compared with breast or colorectal cancer. participants with Hodgkin’s disease or non-Hodgkin’s measure scores. MSAS scores were generally lower in type were related to patient reported outcome of the intervention and an effect size of 0.58. The MSAS physical score rose during chemotherapy −0.10; P<0.001) and the effect size was 0.27. By contrast, psychological, the mean difference was −0.16 (−0.23 to −0.12; P=0.03) in favour of the intervention (table 3). This is equivalent to a Cohen’s effect size of 0.5.

Separate analyses for MSAS sub-domains (table 3) showed that mean MSAS global distress index and MSAS psychological scores decreased in both groups once chemotherapy started. However, they were consistently lower in the intervention group during the trial. Least squares mean was 0.46 in the intervention group compared with 0.67 in the control group, giving a difference of −0.21 (95% confidence interval −0.19 to −0.12; P<0.001) in favour of the intervention (table 3). This is equivalent to a Cohen’s effect size of 0.5.

Primary outcome
Table 2 shows mean total MSAS scores for the intervention and control groups at each assessment. In the intervention group, symptom burden remained at pre-chemotherapy treatment levels over all six chemotherapy cycles. By contrast, the control group reported an increase from cycle 1, which then slowly reduced over the five subsequent chemotherapy cycles. Using an identity link to give results on the original scale, the adjusted analysis least squares means on repeated measures were 0.36 in the intervention arm and 0.52 in the standard care arm, giving a difference of −0.15 (95% confidence interval −0.19 to −0.12; P<0.001) in favour of the intervention (table 3). This is equivalent to a Cohen’s effect size of 0.5.

Supportive care needs tended to be lower for most SCNS-SF34 domains in the intervention group (table 3). Psychological needs followed the same trend as MSAS, with a decrease once chemotherapy started and a larger decrease in the intervention group. The largest observed benefits in the intervention group were for sexuality needs (−1.56, −3.11 to −0.01; P<0.05), patient care and support needs (−1.74, −3.31 to −0.16; P=0.03), and physical and daily living needs (−2.8, −5.0 to −0.6; P=0.01). We found no statistically significant differences for the FACT-G emotional and social domains were not statistically significant.

Enrolment characteristics
Randomisation achieved a good balance between study arms for age, sex, country, cancer type, employment, and educational status (more in the intervention group reported a higher degree). Mean age was 52.4 (SD 12.2) years, and 81.8% were female. Breast cancer was most common (71.4%), and most had early stage (0-II) disease (53.4%). The greatest numbers of participants were recruited from the UK (31.7%) and Greece (31.2%). Half had no comorbidities (table 1).

Adherence to the intervention and alert outcomes
DCTAQ adherence was high for the intervention group at 76.9% (95% confidence interval 74.6 to 79.2); 43 118 DCTAQs completed; 43 118 DCTAQs available). Of these, 3456 generated a red alert and 3746 an amber alert. Some alerts were “linked,” resulting in 3389 (10.2%) linked red alerts and 3649 (11.0%) linked amber alerts. Similarly, clinicians showed a high adherence rate in terms of dealing with AsyMS alerts within specified timeframes (95% of amber alerts and 85% of red alerts) (table 4). Most amber alerts were managed by using self-care advice (n=2241; 60.6%) and acute oncology referral (n=507; 13.7%). For red alerts, self-care (n=1658; 48.0%) and acute oncology referral (n=1207; 35.0%) were also the two most common alert outcomes (table 5).

Adverse events
Adverse events were balanced across study arms. Three deaths occurred in each group. Neutropenic events analyses by country and type of cancer showed that although benefits were seen in all groups, the greatest benefits of the intervention were in participants with breast cancer, Hodgkin’s disease, or non-Hodgkin’s lymphoma in Austria, Ireland, or the UK.

Secondary outcomes
FACT-G scores were higher in the intervention group than the control group across all cycles (table 3) (mean difference 4.06, 95% confidence interval 2.65 to 5.46; P<0.001). Similarly, we found a statistically significant between group mean difference in favour of the intervention group on FACT-G physical (mean difference 1.75, 1.25 to 2.25; P<0.001) and functional (1.61, 1.00 to 2.22; P<0.001) domains. The between group mean differences for the FACT-G emotional and social domains were not statistically significant.

We found statistically significant between group differences for mean scores for STAI-R trait anxiety (table 3) (−1.15, −1.90 to −0.41; P<0.003) and STAI-R state anxiety (−1.13, −2.06 to −0.20; P=0.02) in favour of the intervention group. The intervention group reported greater self-care self-efficacy than the control group (0.85, 0.19 to 1.50; P=0.01).

Table 2 shows mean total MSAS scores for the intervention and control groups at each assessment.

### Primary outcome

#### Enrolment characteristics
Randomisation achieved a good balance between study arms for age, sex, country, cancer type, employment, and educational status (more in the intervention group reported a higher degree). Mean age was 52.4 (SD 12.2) years, and 81.8% were female. Breast cancer was most common (71.4%), and most had early stage (0-II) disease (53.4%). The greatest numbers of participants were recruited from the UK (31.7%) and Greece (31.2%). Half had no comorbidities (table 1).

#### Secondary outcomes
FACT-G scores were higher in the intervention group than the control group across all cycles (table 3) (mean difference 4.06, 95% confidence interval 2.65 to 5.46; P<0.001). Similarly, we found a statistically significant between group mean difference in favour of the intervention group on FACT-G physical (mean difference 1.75, 1.25 to 2.25; P<0.001) and functional (1.61, 1.00 to 2.22; P<0.001) domains. The between group mean differences for the FACT-G emotional and social domains were not statistically significant.

We found statistically significant between group differences for mean scores for STAI-R trait anxiety (table 3) (−1.15, −1.90 to −0.41; P<0.003) and STAI-R state anxiety (−1.13, −2.06 to −0.20; P=0.02) in favour of the intervention group. The intervention group reported greater self-care self-efficacy than the control group (0.85, 0.19 to 1.50; P=0.01).

Supportive care needs tended to be lower for most SCNS-SF34 domains in the intervention group (table 3). Psychological needs followed the same trend as MSAS, with a decrease once chemotherapy started and a larger decrease in the intervention group. The largest observed benefits in the intervention group were for sexuality needs (−1.56, −3.11 to −0.01; P<0.05), patient care and support needs (−1.74, −3.31 to −0.16; P=0.03), and physical and daily living needs (−2.8, −5.0 to −0.6; P=0.01). We found no statistically significant differences for the health system and information needs domain.

#### CASE-Cancer scores were higher in the intervention group than in the control group (mean difference 0.81, 0.19 to 1.43; P=0.01). The WLQ was completed by the 251 patients who were employed, and no significant differences were noted.

#### Adherence to the intervention and alert outcomes
DCTAQ adherence was high for the intervention group at 76.9% (33 156 DCTAQs completed; 43 118 DCTAQs available). Of these, 3456 generated a red alert and 3746 an amber alert. Some alerts were “linked,” resulting in 3389 (10.2%) linked red alerts and 3649 (11.0%) linked amber alerts. Similarly, clinicians showed a high adherence rate in terms of dealing with AsyMS alerts within specified timeframes (95% of amber alerts and 85% of red alerts) (table 4). Most amber alerts were managed by using self-care advice (n=2241; 60.6%) and acute oncology referral (n=507; 13.7%). For red alerts, self-care (n=1658; 48.0%) and acute oncology referral (n=1207; 35.0%) were also the two most common alert outcomes (table 5).

#### Adverse events
Adverse events were balanced across study arms. Three deaths occurred in each group. Neutropenic events...
were higher in the intervention group (125 [64%] vs 71 [36%]). This was expected, as remote monitoring sought to identify these. The numbers of planned (34 vs 38) and unplanned hospital admissions (120 vs 109) were similar in the two groups (table 6). No ASyMS device related incidents were reported.

### Table 1 | Characteristics of participants at enrolment. Values are numbers (percentages) unless stated otherwise

| Characteristics                      | All participants (n=829) | Intervention group (n=415) | Standard care group (n=414) |
|--------------------------------------|--------------------------|---------------------------|-----------------------------|
| Mean (SD) age                        | 52.4 (12.2)              | 51.9 (12.6)               | 52.9 (12.1)                 |
| Female sex                           | 678 (81.8)               | 340 (81.9)                | 338 (81.6)                  |
| Marital status:                      |                          |                           |                             |
| Married                               | 553 (66.7)               | 273 (65.8)                | 280 (67.6)                  |
| Single                                | 129 (15.6)               | 68 (16.4)                 | 61 (14.7)                   |
| Divorced                              | 87 (10.5)                | 45 (10.8)                 | 42 (10.1)                   |
| Widowed                               | 38 (4.6)                 | 14 (3.4)                  | 24 (5.8)                    |
| Not known                             | 22 (2.7)                 | 15 (3.6)                  | 7 (1.7)                     |
| Education:                           |                          |                           |                             |
| Primary                               | 60 (7.2)                 | 30 (7.2)                  | 30 (7.2)                    |
| Secondary                             | 318 (38.4)               | 141 (34.0)                | 177 (42.8)                  |
| University                            | 439 (53.0)               | 235 (56.6)                | 204 (49.3)                  |
| Not known                             | 12 (1.4)                 | 9 (2.2)                   | 3 (0.7)                     |
| Employment:                          |                          |                           |                             |
| Full time                             | 375 (45.2)               | 192 (46.3)                | 183 (44.2)                  |
| Part time                             | 109 (13.1)               | 53 (12.8)                 | 56 (13.5)                   |
| Home maker                            | 82 (9.9)                 | 40 (9.6)                  | 42 (10.1)                   |
| Unemployed                            | 67 (8.1)                 | 34 (8.2)                  | 33 (8.0)                    |
| Retired                               | 173 (20.9)               | 82 (19.8)                 | 91 (22.0)                   |
| Rather not say                        | 23 (2.8)                 | 14 (3.4)                  | 9 (2.2)                     |
| Smoking:                              |                          |                           |                             |
| Never                                 | 414 (49.9)               | 214 (51.6)                | 200 (48.3)                  |
| Ex-smoker                             | 280 (33.8)               | 133 (32.0)                | 147 (35.5)                  |
| Not every day                         | 38 (4.6)                 | 16 (3.9)                  | 22 (5.3)                    |
| Every day                             | 97 (11.7)                | 52 (12.5)                 | 45 (10.9)                   |
| Alcohol consumption:                 |                          |                           |                             |
| Every day                             | 32 (3.9)                 | 18 (4.3)                  | 14 (3.4)                    |
| Occasionally                          | 593 (71.5)               | 306 (73.7)                | 287 (69.3)                  |
| Never                                 | 204 (24.6)               | 91 (21.9)                 | 113 (27.3)                  |
| Country:                              |                          |                           |                             |
| Austria                               | 140 (16.9)               | 71 (17.1)                 | 69 (16.7)                   |
| Greece                                | 259 (31.2)               | 127 (30.6)                | 132 (31.9)                  |
| Ireland                               | 135 (16.3)               | 68 (16.4)                 | 67 (16.2)                   |
| Norway                                | 32 (3.9)                 | 16 (3.9)                  | 16 (3.9)                    |
| UK                                    | 263 (31.7)               | 133 (32.0)                | 130 (31.4)                  |
| No of comorbidities:                 |                          |                           |                             |
| 0                                     | 420 (50.7)               | 220 (53.0)                | 200 (48.3)                  |
| 1-4                                   | 393 (47.4)               | 188 (45.3)                | 205 (49.5)                  |
| ≥5                                    | 16 (1.9)                 | 7 (1.7)                   | 9 (2.2)                     |
| Staging*:                            |                          |                           |                             |
| Stage 0                               | 3 (0.4)                  | 2 (0.5)                   | 1 (0.2)                     |
| Stage I                               | 129 (15.6)               | 63 (15.2)                 | 66 (15.9)                   |
| Stage II                              | 310 (37.4)               | 154 (37.1)                | 156 (37.7)                  |
| Stage III                             | 310 (37.4)               | 157 (37.8)                | 153 (37.0)                  |
| Stage IV†                             | 21 (2.5)                 | 10 (2.4)                  | 11 (2.7)                    |
| Undefined‡                            | 56 (6.8)                 | 29 (7.0)                  | 27 (6.3)                    |
| No of chemotherapy cycles:           |                          |                           |                             |
| 1                                     | 3 (0.4)                  | 3 (0.7)                   | 0                           |
| 2                                     | 4 (0.5)                  | 3 (0.7)                   | 1 (0.2)                     |
| 3                                     | 19 (2.3)                 | 12 (2.9)                  | 7 (1.7)                     |
| 4                                     | 192 (23.2)               | 95 (22.9)                 | 97 (23.6)                   |
| 5                                     | 27 (3.3)                 | 14 (3.6)                  | 13 (3.1)                    |
| 6                                     | 504 (60.8)               | 248 (59.8)                | 256 (61.8)                  |
| 7§                                    | 10 (1.2)                 | 8 (1.9)                   | 2 (0.5)                     |
| 8§                                    | 65 (7.8)                 | 30 (7.2)                  | 35 (8.5)                    |
| 12§                                   | 5 (0.6)                  | 2 (0.5)                   | 3 (0.7)                     |
| Median (range) No of chemotherapy cycles | 6 (1-12)               | 6 (1-12)                  | 6 (2-12)                    |

*TNM/UICC system for breast/colorectal cancer; Ann Arbor Staging System for haematological cancers.
†Not an exclusion criterion for participants with haematological cancer.
‡Data not captured at clinical site before end of trial.
§Until substantial amendment to study protocol was made to limit patients’ participation to ≤6 chemotherapy cycles, first 80 patients enrolled in trial participated until end of their prescribed chemotherapy protocol, and therefore show as having completed >6 cycles.
Table 2 | Descriptive summary of primary outcome – total Memorial Symptom Assessment Scale (MSAS) and sub-domains

| Intervention group | Standard care group |
|--------------------|---------------------|
|                     | No | Mean (SD) | Median (range) | No | Mean (SD) | Median (range) |
| **Total MSAS**       |    |           |                |    |           |                |
| Baseline            | 407 | 0.35 (0.30) | 0.27 (0.1-0.62) | 393 | 0.39 (0.31) | 0.32 (0.1-0.84) |
| Cycle 1             | 367 | 0.33 (0.27) | 0.25 (0.1-0.35) | 340 | 0.51 (0.42) | 0.40 (0.1-0.50) |
| Cycle 2             | 360 | 0.35 (0.28) | 0.28 (0.1-0.58) | 344 | 0.53 (0.60) | 0.44 (0.1-0.25) |
| Cycle 3             | 343 | 0.35 (0.31) | 0.28 (0.1-0.45) | 320 | 0.52 (0.44) | 0.43 (0.1-0.24) |
| Cycle 4             | 304 | 0.37 (0.31) | 0.31 (0.1-0.62) | 280 | 0.53 (0.44) | 0.45 (0.1-0.04) |
| Cycle 5             | 266 | 0.34 (0.29) | 0.27 (0.1-0.45) | 229 | 0.52 (0.41) | 0.44 (0.1-0.22) |
| Cycle 6             | 179 | 0.37 (0.30) | 0.30 (0.1-0.39) | 157 | 0.48 (0.39) | 0.38 (0.1-0.88) |
| **MSAS global distress index** |    |           |                |    |           |                |
| Baseline            | 406 | 0.66 (0.55) | 0.56 (0.3-0.74) | 393 | 0.73 (0.55) | 0.60 (0.3-0.36) |
| Cycle 1             | 366 | 0.42 (0.47) | 0.25 (0.2-0.36) | 337 | 0.66 (0.42) | 0.48 (0.3-0.34) |
| Cycle 2             | 361 | 0.42 (0.46) | 0.28 (0.3-0.38) | 334 | 0.67 (0.41) | 0.51 (0.3-0.12) |
| Cycle 3             | 343 | 0.44 (0.49) | 0.28 (0.2-0.66) | 318 | 0.70 (0.64) | 0.56 (0.3-0.48) |
| Cycle 4             | 304 | 0.46 (0.46) | 0.32 (0.2-0.18) | 277 | 0.69 (0.35) | 0.56 (0.3-0.58) |
| Cycle 5             | 266 | 0.44 (0.29) | 0.27 (0.3-0.40) | 227 | 0.67 (0.57) | 0.56 (0.3-0.68) |
| Cycle 6             | 179 | 0.44 (0.46) | 0.12 (0.2-0.46) | 157 | 0.62 (0.58) | 0.44 (0.2-0.80) |
| **MSAS psychological** |    |           |                |    |           |                |
| Baseline            | 400 | 0.90 (0.80) | 0.63 (0.3-0.57) | 388 | 1.00 (0.77) | 0.84 (0.3-0.83) |
| Cycle 1             | 365 | 0.48 (0.60) | 0.36 (0.2-0.38) | 340 | 0.72 (0.74) | 0.51 (0.3-0.90) |
| Cycle 2             | 359 | 0.46 (0.55) | 0.31 (0.3-0.69) | 334 | 0.68 (0.74) | 0.46 (0.3-0.23) |
| Cycle 3             | 343 | 0.47 (0.61) | 0.26 (0.3-0.07) | 323 | 0.67 (0.74) | 0.46 (0.3-0.74) |
| Cycle 4             | 304 | 0.51 (0.57) | 0.31 (0.2-0.62) | 280 | 0.69 (0.75) | 0.46 (0.3-0.57) |
| Cycle 5             | 266 | 0.48 (0.64) | 0.26 (0.3-0.59) | 231 | 0.65 (0.69) | 0.46 (0.3-0.46) |
| Cycle 6             | 179 | 0.52 (0.62) | 0.31 (0.2-0.71) | 157 | 0.64 (0.68) | 0.51 (0.3-0.83) |
| **MSAS physical**   |    |           |                |    |           |                |
| Baseline            | 406 | 0.27 (0.35) | 0.15 (0.2-0.10) | 395 | 0.31 (0.36) | 0.20 (0.1-0.97) |
| Cycle 1             | 365 | 0.27 (0.31) | 0.17 (0.1-0.54) | 338 | 0.51 (0.47) | 0.38 (0.2-0.36) |
| Cycle 2             | 360 | 0.31 (0.37) | 0.19 (0.2-0.19) | 336 | 0.54 (0.46) | 0.46 (0.2-0.66) |
| Cycle 3             | 344 | 0.34 (0.38) | 0.24 (0.2-0.07) | 319 | 0.56 (0.50) | 0.48 (0.3-0.38) |
| Cycle 4             | 305 | 0.35 (0.36) | 0.25 (0.2-0.01) | 280 | 0.57 (0.51) | 0.47 (0.2-0.97) |
| Cycle 5             | 267 | 0.32 (0.34) | 0.20 (0.1-0.51) | 226 | 0.56 (0.47) | 0.43 (0.2-0.26) |
| Cycle 6             | 179 | 0.34 (0.33) | 0.26 (0.1-0.71) | 157 | 0.49 (0.45) | 0.38 (0.2-0.20) |

Discussion

To our knowledge, this trial is the first to evaluate the efficacy of real time remote monitoring of chemotherapy toxicity across multiple countries and to focus mainly on people being treated with curative intent. Overall, symptom burden in the intervention group was effectively controlled, remaining at pre-treatment levels throughout the trial. Similar findings have been reported previously; however, these earlier studies were conducted in a single country and healthcare system.10-13

The greatest improvements were seen in patients with breast cancer, Hodgkin's disease, or non-Hodgkin’s lymphoma in Austria, Ireland, and the UK. Reasons for differences are unclear, but because ASyMS was developed in the UK it may work best in similar healthcare systems. However, why symptom burden was higher in Norwegian participants is not clear, although it may be because the number of patients from Norway was insufficient to show any difference, eSMART, like other studies,11,12 found changes in symptom burden over consecutive chemotherapy cycles. Our findings suggest that benefits of remote monitoring begin within the first three cycles of treatment and are sustained over time, indicating that systems such as ASyMS should be implemented at the start of treatment.

Patients in the intervention group attributed improvements when using ASyMS in terms of enabling real time reporting, the embedded alert algorithms, and direct links to their hospital and oncology team, all of which facilitated timely access to quality care. Similarly, clinicians’ experiences indicated that clinical algorithms and real time symptom reporting enabled provision of targeted and more effective interventions for symptoms. Forthcoming publications will report on patients’ and clinicians’ experiences of the intervention in more detail.

We considered, by convention, that the larger the Cohen’s effect size beyond the 0.25 cut-off point the stronger the indication is for a clinically important change in our primary outcome between intervention and control. From the perspective of clinical importance, the mean between group difference of 0.15 in total MSAS scores translated into an effect size of 0.15 in total MSAS scores translated into an effect size of 0.15 in total MSAS scores translated into an effect size of 0.15 in total MSAS scores translated into an effect size of 0.15 in total MSAS scores translated into an effect size of 0.15 in total MSAS scores...
Table 4 | Clinicians’ adherence to time when handling alerts

| Type of alert | No of alerts generated | No of linked alerts | No (%) of linked alerts viewed within timescale* |
|---------------|------------------------|---------------------|-----------------------------------------------|
| Red alert     | 3456                   | 3389                | 2883 (85.1)                                   |
| Amber alert   | 3746                   | 3649                | 3467 (95.0)                                   |
| Overall       | 7202                   | 7038                | 6350 (90.2)                                   |

*Time was measured from when first linked alert arrived at server to time when clinician first viewed alert. ‡Target time was 30 minutes. †Target time was 8 hours.

of 0.5, which is considered “medium” according to Cohen’s criteria. This finding is promising and further substantiates our statistically significant results, pointing to a positive, clinical impact on symptom experience when self-reported symptoms were remotely monitored via ASyMS. Our Cohen’s effect sizes ranged between 0.42 and 0.58 and so are either comparable to or larger than previously reported effect sizes. In a randomised controlled trial testing a symptom monitoring app during neoadjuvant chemotherapy for breast cancer, Fjell et al reported an effect size of 0.26 for between group differences in total MSAS (and 0.34 for MSAS global distress index scores) two weeks after treatment completion. Effect sizes of 0.01-0.21 for between group differences in MSAS global distress index were reported in a randomised controlled trial of computerised patient reported symptom monitoring during one to four weeks of radiotherapy.41

eSMART showed significant improvements in anxiety, health related quality of life, self-efficacy, and supportive care needs in the intervention group. The improvements in health related quality of life are consistent with findings from recent trials using remote monitoring systems in chemotherapy care. Although Basch et al reported similar results using the EuroQol five dimension (EQ-5D) questionnaire, the dimensions are assessed by a single item. We used a validated patient reported outcome measure that comprehensively assessed each of these outcomes and provides more detailed findings about the impact of remote monitoring systems not only on health related quality of life but also on self-efficacy and supportive care needs. Our findings suggest that ASyMS has a broader impact, but further analyses using techniques such as parallel process growth modelling are needed to evaluate concurrent changes in symptom burden and health related quality of life outcomes.

eSMART is the first randomised controlled trial in people with cancer to assess the effect of remote symptom monitoring on anxiety by using a validated patient reported outcome measure. ASyMS was associated with statistically significant improvements in anxiety. Our findings may differ from relatively small post-intervention effects on psychological symptoms reported in literature pertinent to routine use of patient reported outcome measures31; however, they are consistent with earlier studies of ASyMS in which participants reported feelings of enhanced safety and reassurance. Anxiety is the most common psychological symptom after a diagnosis of cancer and is higher among people with cancer than in the general population, so these effects may benefit a large proportion of oncology patients; however, this needs to be confirmed in future studies.

Patients using ASyMS reported a statistically significant improvement in self-efficacy, which is consistent with results from the eRAPID trial11. Daily symptom reporting with real time clinician support for moderate-severe symptoms and provision of tailored self-care information are novel features of ASyMS and are likely to promote greater self-efficacy. Other remote monitoring systems that assess symptoms less frequently—for example, weekly—may have limited potential to encourage patients to learn self-management strategies. Likewise, providing real time support from clinicians may engender a greater sense of control. Although other systems integrate symptom reports with patients’ health records, they do not alert clinicians to contact patients within a specified time. Instead, the onus is on patients to contact clinicians when symptoms occur. Recent research on neutropenic sepsis showed that patients are reluctant to report symptoms in a timely manner.7

Table 5 | Clinical responses following Advanced Symptom Management System (ASyMS) alerts

| Outcome                          | No of amber alerts | No of red alerts |
|----------------------------------|--------------------|-----------------|
| Self-care                        | 2241               | 1658            |
| Acute oncology referral          | 507                | 1207            |
| Patient not contacted            | 305                | 0               |
| Other                            | 317                | 257             |
| Unable to contact patient; amber alert closed | 150             | -               |
| No intervention recorded         | 60                 | 178             |
| Out of hours services            | 38                 | 18              |
| Emergency services referral      | 25                 | 77              |
| General practitioner referral    | 37                 | 29              |
| Hospital referral: clinic review | 7                  | 11              |
| Hospital referral: general ward  | 6                  | 5               |
| Hospital referral: acute oncology referral | 5               | 5               |
| Hospital referral: emergency department | 3               | 4               |
| Hospital referral: specialist    | 3                  | 2               |
| District nurse referral          | 2                  | 1               |
| Palliative care team: hospital   | 2                  | 1               |
| Total*                           | 3698               | 3453            |

*Totals are greater than number of alerts as healthcare professionals could select more than one outcome.
Table 6 | Adverse events. Values are numbers (percentages)

| Adverse event               | All patients | Intervention group | Normal care group |
|-----------------------------|--------------|--------------------|-------------------|
| Death*                      | 6            | 3 (50)             | 3 (50)            |
| Neutropenic sepsis event†   | 196          | 125 (64)           | 71 (36)           |
| Planned hospital admission† | 72           | 34 (47)            | 38 (53)           |
| Unplanned hospital admission†| 229          | 120 (52)           | 109 (48)          |

*Collected in case note reviews.
†Collected in Promasys.

may have been an easily accessible information source. Furthermore, because patients using ASyMS had reduced symptom burden and anxiety, and better health related quality of life, they may have been more inclined to engage in sexual activity.

Evaluating work limitations was an important component of eSMART given the impact of cancer treatment on employment.49 50 Work limitation scores were not statistically significantly different between the two groups. This finding is not consistent with a previous study that reported significant work limitations in patients undergoing curative chemotherapy.51 However, our results should be interpreted with caution, as only participants who were working completed this patient reported outcome measure.

Patients’ and clinicians’ adherence to the intervention was very good and compares favourably with similar studies that report slightly lower adherence rates,11 especially given that eSMART required daily assessments, which some people may consider onerous.

Importantly, our randomised controlled trial found that the safety of ASyMS was satisfactory, with no device related incidents reported. Adverse events were balanced between the two groups, each with three deaths and similar rates of hospital admission. This is not surprising, however, as hospital admission rates in this population are relatively low. The incidence of neutropenic events was higher in the intervention arm, but this was expected as greater identification was the intervention’s intent.

Approximately 30% of patients approached declined participation, with 27% not giving a reason. Those who did mainly cited the psychological impact of diagnosis and limited confidence with technology. Our take-up rate is similar to that in comparable studies that recruited a mix of participants being treated with curative and palliative intent and higher than in those that recruited patients with advanced disease.11 12 Anecdotally, clinicians also reported that the intensity of the study at a time when people were feeling stressed about starting treatment was a common concern of those who declined participation. However, the high patient adherence rates seen in this trial serve as a positive indicator of the usability and adoption of ASyMS by patients within the context of their chemotherapy treatment.

Strengths and limitations of study
This is the largest trial to date of remote monitoring of symptoms during chemotherapy for cancers being treated with curative intent. Notable strengths of this study include its robust randomised controlled trial design, fully powered sample size, longitudinal assessments of symptoms and outcomes, and multi-diagnosis, multisite, and multi-country deployment. Our study, therefore, avoided many limitations of previous studies of remote monitoring that tended to evaluate deployment at single sites and to recruit patients from a single diagnostic group. Our attrition rate was considerably lower than expected and comparable to those in similar studies,11 12 demonstrating external validity and high acceptability of the intervention to patients and clinicians.

Our study does, however, have limitations. Firstly, almost three quarters of participants had breast cancer and were female; however, this is a common limitation of supportive cancer care research and reflects the high incidence of breast cancer in Europe. Careful consideration was given before clinical sites were permitted to recruit greater numbers of patients with breast cancer than originally intended, but we judged it more important that the study achieved power than that the proposed diagnostic breakdown was achieved without sufficient power. We recruited participants with Hodgkin’s disease, non-Hodgkin’s lymphoma, and colorectal cancer, so we have evidence that ASyMS could be beneficial in these populations as well. However, with a small number of participants with Hodgkin’s disease or non-Hodgkin’s lymphoma, a larger study is warranted. Seven patients were excluded after randomisation, but associated bias was reduced as numbers were equally distributed between the study groups. Although patients and clinicians were aware of the allocation, trial statisticians were blinded throughout the analysis. Finally, we encountered technical challenges across all sites owing to the connectivity of ASyMS SIM cards, meaning that patients using ASyMS reverted to standard care for approximately two weeks to ensure patient safety while this technical problem was resolved. Although technical testing indicated that this was not related to the ASyMS device, it may have affected overall eSMART results.

Implications for clinicians and for policy
The results of eSMART support the use of remote symptom monitoring in routine care for patients treated with curative intent. When combined with findings of comparable randomised controlled trials,10 12 52 these results support the incorporation of remote symptom monitoring technologies into evidence based guidelines on symptom management in people with cancer. Governments and health organisations are increasingly responding to the rapidly evolving digital health landscape to provide optimal services and care— even more so in response to the covid-19 pandemic—and they recognise ways in which these technologies can disrupt, and are disrupting, the status quo.53 Many government policies prioritise empowerment of citizens, enhanced self-management, and digitally enabled access to services.54 Our findings suggest that
an evidence based remote monitoring intervention, such as ASyMS, has potential for implementation into routine care to make a meaningful difference to people with cancer.

Conclusion
The results of eSMART suggest that ASyMS is an effective intervention for reducing symptom burden and improving health related quality of life during adjuvant chemotherapy across a range of cancers. Use of ASyMS was associated with significant reductions in anxiety and improvements in several supportive care needs and self-efficacy domains. Moreover, results were consistent across five European countries, although perhaps with greater impact in Austria, the Republic of Ireland, and the UK. Our success in implementing ASyMS across several diverse health systems suggests that the system can be easily scaled up and adapted for use in various international settings.

Improving symptom management by using remote monitoring systems such as ASyMS is essential. Future research should combine artificial intelligence with the use of real world data to develop predictive, personalised, and targeted interventions. These approaches are likely to lead to improvements in patients’ outcomes and efficiencies in care. Evaluation of the efficacy of remote symptom monitoring systems such as ASyMS for other treatment modalities (for example, targeted therapies) is needed. The ultimate vision is to have a multimodal seamless system of remote symptom monitoring used from the start of treatment and through survivorship.

Our findings are relevant in the context of the covid-19 pandemic. The cancer community faces unprecedented challenges in delivering chemotherapy, but ASyMS can provide a safe, secure, and “real time” system that optimises symptom management and supports patients to remain at home. Essentially, the system can expedite informed and appropriate patient triage and enable clinicians to care for multiple patients in real time, using digital lines of communication to deliver high quality and safe care at a distance.

AUTHOR AFFILIATIONS

1Computer and Information Sciences, University of Strathclyde, Glasgow, UK
2School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK
3Leven, UK
4University of Surrey, School of Health Sciences, Guildford, UK
5National and Kapodistrian University of Athens School of Health Sciences, Athens, Greece
6School of Nursing, Midwifery and Health Systems, University College Dublin, Dublin, Ireland
7Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
8School of Health Services and Population Research, King’s College London Institute of Psychiatry Psychology and Neuroscience, London, UK
9Department of Health Sciences, NTNU, Gjøvik, Norway
10University of California San Francisco, San Francisco, CA, USA
11European Cancer Patient Coalition, Brussels, Belgium
12NHS 24, Glasgow, UK
13Docobo Limited, Leatherhead, UK
14School of Medicine, University College Dublin, Dublin, Ireland
15Surrey Clinical Trials Unit, University of Surrey, Guildford, UK
16Johnson and Johnson Medical, Norderstedt, Germany
17Population Health and Genomics, Medical School, University of Dundee, Dundee, UK

We thank the participants and professionals across our partner hospital sites for taking part and positively contributing to eSMART (Medical University Vienna Comprehensive Cancer Centre, Austria; Agios Anargiri Cancer Hospital, Greece; Metropolitan Hospital, Greece; Air Force General Hospital, Greece; St James’ Hospital, Ireland; St Vincent’s Private Hospital, Ireland; St Vincent’s University Hospital, Ireland; Innlandet Hospital Trust Division Gjøvik-Lillehammer, Norway; Guy’s and St Thomas’ NHS Foundation Trust, UK; Mount Vernon Cancer Centre, UK; St George’s Healthcare Trust, UK, and University College London Hospitals, UK). We also thank the Data Monitoring Committee, researchers, and eSMART partners for their dedicated efforts to this trial.

Contributors: RM, LM, GK, NK, ER, JA, PF, EP, EF, PF, AG, PMcC, GB, CM, DO, AF, SK, and PTD obtained funding for the research. All authors contributed to either the design or conduct of the study. NDS did the statistical analyses, supervised by PTD. RM, PTD, and LM produced the first draft of this manuscript, and all authors reviewed, edited, and approved the final version. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria were omitted. RM and PTD are the guarantors.

Funding: This trial was funded by the European Commission via the FP7-HEALTH-2013-INNOVATION-1 grant award scheme, grant number 602289. The trial was sponsored by the University of Strathclyde. The views expressed in this article are those of the authors and not necessarily those of the European Commission or the University of Strathclyde. The funders and the sponsors of the trial had no role in the design, undertaking, and reporting of the study. The funders received status reports.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: financial support from the European Commission for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: The study was approved by NHS Lothian South East Scotland Research Ethics Committee 02, reference number 14/ SS/1062. The study received local clinical site ethical approvals in each partner country before it started. All participants gave written informed consent.

Data sharing: The study protocol was published previously. Data will not be released to any external parties for the first 12 months following publication of this manuscript. After this time, requests for access to de-identified individual participant data that underlie the results reported in this article should be addressed to the corresponding author and should include clear and specified plans of how the data are to be used. All proposals for data use will need approval of the eSMART consortium partner leads before any data are released.

The lead authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities: The European Cancer Patient Coalition will disseminate the findings of eSMART to relevant patient and public communities across Europe; however, dissemination of the results to the eSMART participants is not possible.

Provenance and peer review: Not commissioned; externally peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.

1 Devenij EJ, Denison LA, Whifford HS. Cancer Treatment Side Effects: A Meta-analysis of the Relationship Between Response Expectancies and Experience. J Pain Symptom Manage 2017;54:245-258.e2. doi:10.1016/j.jpainsymman.2017.03.017
1. Shin H, Visvanathan K, Thorne T, Wolfs AF. Breast cancer surveillance care beyond local and systemic therapy. Breast 2019;48(Suppl 1):S103-9. doi: 10.1016/S0960-9776(19)31135-X.

2. Tai E, Gu P. Detracts A, Richardson IC. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012. J Oncol Pract 2017;13:e562-61. doi: 10.1200/JOP.2016.019588.

3. Coober D, A van der Heede K, Vanhove E, De Bom A, Milisen K. Wildiers H. Immediate versus delayed self-reporting of symptoms and side effects during chemotherapy: does timing matter? Eur J Oncol Nurs 2011;15:130-6. doi: 10.1016/j.ejon.2010.06.010.

4. Cunico KR. Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature. Clin J Oncol Nurs 2016;20:144-51. doi: 10.1188/16.CJON.20-014AP.

5. Oakley CM, et al. Patients making potentially life threatening delays in reporting neutropenic sepsis. Grounded theory study. J Clin Oncol 2016;35:S57-46. doi: 10.1200/JCO.2015.65.1156. suppl.e1560.

6. Loiselle G, Ahmed S. Is Connected Health Contributing to a Healthier Population? Med Internet Res 2017;19:e386. doi: 10.2196/10813.

7. Lehoux P, Roncarolo F, Silva HP, Boivin A, Denis JL, Hébert R. What Health System Challenges Should Responsible Innovation in Health Address? Insights from an International Scoping Review. Int J Health Policy Manag 2019;8:63-75. doi: 10.15171/ijhpm.2018.110.

8. Mooney KH, Beck SL, Wong B, et al. Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT. Cancer Med 2017;6:537-46. doi: 10.1002/cam4.1002.

9. Absalom K, Warrington L, Hudson E, et al. Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy. J Clin Oncol 2021;39:734-47. doi: 10.1200/JCO.2020.02015.

10. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 2016;34:557-65. doi: 10.1200/JCO.2015.63.0930.

11. Denis F, Basch E, Septans AL, et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. AMA 2019;321:306-7. doi: 10.1001/jama.2018.18085.

12. Liaoze T, Basch E, Trémolières P, et al. Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer. Thorac Oncol 2019;14:1012-20. doi: 10.1016/j.jtho.2019.02.005.

13. Osborn J, Alajary A, Cooksey T, Subbe CP. Do mHealth applications improve clinical outcomes of patients with cancer? A critical appraisal of the peer-reviewed literature. Support Care Cancer 2020;28:1469-79. doi: 10.1007/s00520-019-04955-v.

14. Moradian S, Voelker N, Brown C, Liu G, Howell D. Effectiveness of Internet-based interventions in managing chemotherapy-related symptoms in patients with cancer: a systematic literature review. Support Care Cancer 2018;26:361-74. doi: 10.1007/s00520-017-3900-8.

15. Lennon MR, Bouamrane MM, Devlin AM, et al. Readiness for Delivering Digital Health at Scale: Lessons from a Longitudinal Qualitative Evaluation of a National Digital Health Innovation Program in the United Kingdom. J Med Internet Res 2017;19:e42. doi: 10.2196/jmir.6900.

16. Shafisahvari H, Matynourpun P, Ghasvandian S, Nejad MRG. Medical Research Council framework for development and evaluation of complex interventions: A comprehensive guide. Educ Health Promot 2020;9:88. doi: 10.4103/ehhp.46_19.

17. O’Callaghan A, Croot L, Duncan E, et al. Guidance on how to develop complex interventions to improve health and healthcare. BMJ Open 2019;9:e029954. doi: 10.1136/bmjopen-2019-029954.

18. Kearney N, McCann L, Norrie J, et al. Evaluation of a mobile phone-based advanced Symptom Management System (ASyMS) to monitor and manage chemotherapy-related toxicity. Eur J Oncol Nurs 2008;12:380-6. doi: 10.1016/j.ejon.2008.04.007.

19. McCann L, Maguire R, Miller M, Kearney N. Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy-related toxicity. Eur J Cancer Care (Engl) 2009;18:156-64. doi: 10.1111/j.1365-2354.2008.00938.x.

20. Maguire R, Fox PA, McCann L, et al. The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS)-remot technology for patients with cancer. BMJ Open 2017;7:e015016. doi: 10.1136/bmjopen-2016-015016.

21. Brant JM, Beck SL, Dudley WN, Cobb P, Pepper G, Maïskowski C. Symptom trajectories during chemotherapy in outpatients with breast cancer. J Clin Oncol 2011;29:470-7. doi: 10.1200/JCO.2010.12.002.

22. Maguire R, Kotronoulas G, Donnan PT, et al. Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity. The Daily Chemotherapy Toxicity Self-Assessment Questionnaire. Eur J Cancer Care (Engl) 2018;27:e12890. doi: 10.1111/ecc.12890.

23. Furlong E, Darley A, Fox P, et al. Adaptation and Implementation of a Mobile-Phone-Based Remote Symptom Monitoring System for People With Cancer in Europe. J Med Internet Res 2019;5:e015016. doi: 10.2196/10813.

24. den Naurois J, Novitzky-B assays I, Gill MJ, Marty FM, Cullen MH, Rola F. EMSO Guidelines Working Group. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(Suppl 5):v25-62. doi: 10.1093/annonc/mdq196.

25. European Commission DG Enterprise and Industry. Guidelines on a Medical Devices Vigilance System. 2009. http://www.meddev. europa.eu/documents/2_12_1-rev_6-12-2009_en.pdf.

26. Porteny RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Cancer 1993;48A:1326-36. doi: 10.1002/1099-0549(94)90182-1.

27. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9. doi: 10.1200/JCO.1993.11.3.570.

28. Boyes A, Girgis A, Lecathelinais C. Brief assessment of advanced cancer patients’ perceived needs: development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34). J Clin Pract 2015;62:603-10. doi: 10.1097/EJC.0000000000000271.

29. Spießberger C, Gorsch RL, Lushere R. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, 1983.

30. Wolf MS, Chang CH, Davis T, Makoul G. Development and validation of a Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer). Patient Educ Couns 2005;57:333-41. doi: 10.1016/j.pec.2004.09.005.

31. Lerner D, Reed J, Massarotti E, Wester LM, Burke TA. The Work Limitations Questionnaire’s validity and reliability among patients with osteoarthritis. J Clin Epidemiol 2002;55:197-208. doi: 10.1016/S0895-4356(01)00424-3.

32. Wong DM, Chang CH, Davis T, Makoul G. Development and validation of a clinical tool to enable daily monitoring of symptoms during chemotherapy: does timing matter? Eur J Oncol Nurs 2011;15:470-7. doi: 10.1016/j.ejon.2010.12.002.

33. Maguire R, Kertonoulas G, Donnan PT, et al. Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity. The Daily Chemotherapy Toxicity Self-Assessment Questionnaire. Eur J Cancer Care (Engl) 2018;27:e12890. doi: 10.1111/ecc.12890.
44 Maguire R, Connaghan J, Arber A, et al. Advanced Symptom Management System for Patients with Malignant Pleural Mesothelioma (ASyMSmeso): Mixed Methods Study. J Med Internet Res 2020;22:e19180. doi:10.2196/19180

45 Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry 2020;25:1487-99. doi:10.1038/s41380-019-0595-x

46 Paterson CL, et al. Trajectories of anxiety among breast cancer patients treated with chemotherapy pre- and post-chemotherapy compared to healthy controls: A nationwide multicenter study. J Clin Oncol 2017;35(suppl):e21711. doi:10.1200/JCO.2017.35.15_suppl.e21711

47 Ben Cherif A, Bouthil AD, Courbiere B, et al. Patient Discussion About Sexual Health With Health Care Providers After Cancer—A National Survey. J Sex Med 2016;13:1686-94. doi:10.1016/j.jsxm.2016.09.005

48 O’Connor SR, Connaghan J, Maguire R, et al. Healthcare professional perceived barriers and facilitators to discussing sexual wellbeing with patients after diagnosis of chronic illness: A mixed-methods evidence synthesis. Patient Educ Couns 2019;102:850-63. doi:10.1016/j.pec.2018.12.015

49 Dumas A, Vaz Luis I, Bovagnet T, et al. Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). J Clin Oncol 2020;38:734-43. doi:10.1200/JCO.19.01726

50 van Muijen P, Duijts SFA, Bonefaas-Groenewoud K, van der Beek AJ, Anema JR. Predictors of fatigue and work ability in cancer survivors. Occup Med (Lond) 2017;67:703-11. doi:10.1093/occmed/kqx165

51 Tevairaiwak A, et al. Prospective study of work limitations in cancer patients (pts) undergoing curative chemotherapy (CT). J Clin Oncol 2017;35(suppl):18. doi:10.1200/JCO.2017.35.5_suppl.18

52 Velikova G, et al. Phase III randomized controlled trial of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and advice)—An eHealth intervention during chemotherapy. J Clin Oncol 2020;38(suppl):7002. doi:10.1200/JCO.2020.38.15_suppl.7002

53 Whitelaw S, Mamas MA, Topol E, Van Spall HGC. Applications of digital technology in COVID-19 pandemic planning and response. Lancet Digit Health 2020;2:e435-40. doi:10.1016/S2589-7500(20)30142-4

54 European Commission. Consultation: Transformation Health and Care in the Digital Single Market. 2018. https://www.digitalhealthnews.eu/download/publications/5538-consultation-transformation-health-and-care-in-the-digital-single-market.

55 Al-Shamsi HO, Alhazzani W, Alhruraiji A, et al. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic. An International Collaborative Group. Oncologist 2020;25:e936-45. doi:10.1634/theoncologist.2020-0213